StockData
MediciNova Inc logo

MediciNova Inc (MNOV) shareholders

MNOVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$1.34+0.00 (0.00%)

Close on Nov 17, 2026Market cap $65.96MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
10.5%
5M of 49M shares
Institutional holders
29
3 new, 4 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $1.73M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
3D Investment Partners Pte. Ltd.
Joint filing with 3D Opportunity Master Fund (9.90%)
4,862,0479.90%13D (active) amendmentSep 25, 2026
Vanguard Capital Management
Joint filing with Vanguard Morningstar Total Stock Market Index Fund (5.37%)
3,548,7317.20%13G (passive)Sep 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of MNOVValueChange% of portfolio
Essex Woodlands Management, Inc.1,105,9412.25%$1.46M–0.57%
BlackRock, Inc.752,0911.53%$992.76K+46,1370.00%
Citigroup Inc635,7151.29%$839.14K–0.00%
Vanguard Capital Management LLC609,0521.24%$803.95K−1,9870.00%
Geode Capital Management, LLC539,3121.10%$712.09K−4,5310.00%
Vanguard Fiduciary Trust Co282,6080.57%$373.04K+1,9870.00%
UBS Group AG222,2000.45%$293.30K–0.00%
Renaissance Technologies LLC205,4000.42%$271.13K+15,5000.00%
State Street Corp193,6980.39%$255.68K–0.00%
Northern Trust Corp143,6650.29%$189.64K+10,5020.00%
Bank of New York Mellon Corp78,2770.16%$103.33K–0.00%
Charles Schwab Investment Management Inc71,5060.15%$94.39K–0.00%
Bridgeway Capital Management, LLC56,0310.11%$73.96K–0.00%
SBI Securities Co., Ltd.51,4790.10%$67.95K+6,6030.00%
Dimensional Fund Advisors LP50,5520.10%$66.73K–0.00%
Barclays PLC42,8060.09%$56.50K−120,0940.00%
Schonfeld Strategic Advisors LLC36,1570.07%$47.73K−2190.00%
Susquehanna International Group, Llp26,7520.05%$35.31K−17,1740.00%
Jane Street Group, LLC15,8180.03%$20.88K−71,2670.00%
Vanguard Global Advisers, LLC15,5990.03%$20.59K–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026295M10.5%3 / 58 / 40M0M
Q1 2026305M11.0%5 / 89 / 71M0M
Q4 2025335M10.7%9 / 89 / 20M0M
Q3 2025265M10.4%4 / 86 / 10M0M
Q2 2025235M10.5%0 / 49 / 50M0M
Q1 2025285M10.6%2 / 710 / 40M0M
Q4 2024305M10.6%5 / 115 / 50M0M
Q3 2024305M10.0%4 / 511 / 61M0M
Q2 2024335M9.7%5 / 215 / 70M0M
Q1 2024355M9.6%5 / 712 / 40M0M
Q4 2023345M10.1%6 / 108 / 20M0M
Q3 2023305M10.2%3 / 512 / 70M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

14 funds held MNOV in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of MNOVValue% of fundAs of
Vanguard Extended Market Index Fund609,0521.24%$803.95K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund255,1410.52%$346.99K0.00%May 31, 2026
iShares Micro-Cap ETF158,9760.32%$209.85K0.01%Jun 30, 2026
Fidelity Total Market Index Fund87,5750.18%$119.10K0.00%May 31, 2026
Schwab Total Stock Market Index Fund71,5060.15%$95.10K0.00%Jul 31, 2026
Fidelity Series Total Market Index Fund68,4060.14%$93.03K0.00%May 31, 2026
Ultra-Small Company Market Fund50,2470.10%$66.33K0.04%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund25,9660.05%$35.31K0.00%May 31, 2026
Small Cap Core Fund13,8940.03%$18.34K0.00%Jun 30, 2026
1290 VT Micro Cap Portfolio10,5250.02%$13.89K0.01%Jun 30, 2026
LVIP Dimensional U.S. Core Equity 2 Fund6,6930.01%$8.83K0.00%Jun 30, 2026
AST Small-Cap Equity Portfolio4,9300.01%$6.51K0.00%Jun 30, 2026
JNL/DFA U.S. Small Cap Fund3,0000.01%$3.96K0.00%Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund1000.00%$1320.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Yuichi IwakiPresident and CEO1,091,9332.22%Jan 20, 2026
Kazuko MatsudaChief Medical Officer322,9960.66%Jan 20, 2026
Hideki NagaoDirector0–Jun 25, 2026
Carolyn BeaverDirector––Jun 25, 2026
Nicole LemerondDirector––Jun 25, 2026
Opportunity Master Fund 3D–4,862,0479.88%Sep 29, 2026
Investment Partners Pte. Ltd. 3D–––Sep 29, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Opportunity Master Fund 3D
–
Sep 25, 2026Sale−640,000$2.70$1.73M4,862,047
Hideki Nagao
Director
Nov 28, 2022Sale−6,754$2.25$15.20K0
Hideki Nagao
Director
Nov 22, 2022Sale−218$2.13$4646,754
Hideki Nagao
Director
Nov 21, 2022Sale−5,365$2.18$11.70K6,972
Hideki Nagao
Director
Nov 17, 2022Sale−309$2.18$67412,337
Kazuko Matsuda
Chief Medical Officer, Director
Aug 23, 2021Option exercise+60,000$2.30$138.00K322,996
Yuichi Iwaki
President and CEO, Director
Jul 9, 2021Option exercise+39,583$2.54$100.54K966,933
Kazuko Matsuda
Chief Medical Officer, Director
Jun 24, 2021Option exercise+46,554$2.54$118.25K206,746
Kazuko Matsuda
Chief Medical Officer, Director
Jun 24, 2021Option exercise+56,250$2.46$138.38K262,996
Geoffrey OBrien
Vice President
May 19, 2021Option exercise+11,318$2.46$27.84K48,318
Geoffrey OBrien
Vice President
May 19, 2021Option exercise+32,000$2.54$81.28K37,000
Hideki Nagao
Director
Mar 11, 2021Sale−2,354$7.40$17.42K12,646
Yuichi Iwaki
President and CEO, Director
Feb 25, 2021Option exercise+86,250$2.46$212.18K927,350
Hideki Nagao
Director
Sep 15, 2020Sale−1,000$5.78$5.78K15,000
Hideki Nagao
Director
Aug 6, 2020Option exercise+15,000$2.58$38.70K16,000
Kazuko Matsuda
Chief Medical Officer, Director
Jun 12, 2020Option exercise+20,000$5.13$102.60K160,192
Yuichi Iwaki
President and CEO, Director
Apr 8, 2020Option exercise+60,417$2.54$153.46K841,100
Kazuko Matsuda
Chief Medical Officer, Director
Apr 8, 2020Option exercise+28,446$2.54$72.25K140,192
Kazuko Matsuda
Chief Medical Officer, Director
Mar 13, 2020Buy+2,000$3.62$7.24K111,746
Kazuko Matsuda
Chief Medical Officer, Director
Mar 13, 2020Buy+2,000$3.62$7.24K111,476
Yuichi Iwaki
President and CEO, Director
Mar 12, 2020Buy+20,000$3.10$62.00K780,683
Kazuko Matsuda
Chief Medical Officer
Jun 12, 2019Option exercise+37,000$4.80$177.60K109,457
Hideki Nagao
Director
May 13, 2019Option exercise+1,000$2.77$2.77K1,000
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+42,500$4.10$174.25K460,530
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+80,000$4.10$328.00K418,030
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+105,000$2.64$277.20K565,530
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+120,000$3.91$469.20K835,530
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+30,000$3.91$117.30K715,530
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+15,000$3.24$48.60K580,530
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+100,000$6.10$610.00K935,530
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+105,000$7.00$735.00K1,040,530
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+35,700$7.34$262.04K189,280
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+85,000$2.54$215.90K274,280
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+63,750$2.46$156.83K338,030
Masatsune Okajima
VP and Head of Japanese Office
Feb 28, 2019Option exercise+105,000$3.09$324.45K685,530
Masatsune Okajima
VP and Head of Japanese Office
Jan 9, 2019Option exercise+41,250$2.20$90.75K153,580
Yuichi Iwaki
President and CEO, Director
Jan 3, 2019Option exercise+18,572$2.20$40.86K759,392
Yuichi Iwaki
President and CEO, Director
Mar 5, 2018Option exercise+50,003$2.20$110.01K740,594
Yuichi Iwaki
President and CEO, Director
Jan 3, 2018Option exercise+53,363$4.42$235.86K690,591
Masatsune Okajima
VP and Head of Japanese Office
Dec 12, 2017Option exercise+48,000$4.42$212.16K108,941
Yuichi Iwaki
President and CEO, Director
Nov 2, 2017Option exercise+21,067$4.42$93.12K637,228
Yoshio Ishizaka
Director
Aug 21, 2017Buy+5,000$5.17$25.85K10,000
Yutaka Kobayashi
Director
May 15, 2017Buy+1,000$5.60$5.60K25,000
Yutaka Kobayashi
Director
May 12, 2017Buy+24,000$5.62$134.88K24,000
Yutaka Kobayashi
Director
Sep 15, 2016Buy+11,800$6.44$75.99K81,800
Yutaka Kobayashi
Director
Sep 9, 2016Buy+10,000$6.67$66.70K70,000
Geoffrey OBrien
Vice President
Jul 5, 2016Option exercise+3,300$4.80$15.84K8,300
Geoffrey OBrien
Vice President
Jul 5, 2016Sale(10b5-1 plan)−3,300$8.00$26.40K5,000
Kazuko Matsuda
Chief Medical Officer
Mar 14, 2016Option exercise+800$3.56$2.85K62,003
Masatsune Okajima
VP and Head of Japanese Office
Mar 14, 2016Option exercise+8,400$3.56$29.90K51,138
Yutaka Kobayashi
Director
Dec 10, 2014Buy+12,000$3.54$42.48K60,000
Yutaka Kobayashi
Director
Nov 26, 2014Buy+10,000$3.07$30.70K48,000
Yutaka Kobayashi
Director
Nov 20, 2014Buy+13,000$3.19$41.47K38,000
Yoshio Ishizaka
Director
Nov 19, 2014Buy+5,000$2.86$14.30K5,000
Yutaka Kobayashi
Director
Sep 11, 2014Buy+10,000$2.95$29.50K25,000
Yutaka Kobayashi
Director
Sep 3, 2014Buy+100$2.66$2665,100
Yutaka Kobayashi
Director
Sep 3, 2014Buy+5,000$2.63$13.15K5,000
Yutaka Kobayashi
Director
Sep 3, 2014Buy+9,900$2.67$26.43K15,000
Tatsuo Izumi
Director
Dec 12, 2013Sale−970$2.17$2.10K600,000
Tatsuo Izumi
Director
Dec 12, 2013Sale−70,300$2.10$147.63K600,970

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.66%
0M shares short
Days to cover
5.4
At 0M shares a day
Change since last report
-2.4%
From 0M shares
Short volume, 20 days
50.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MediciNova's stock actually held short. Settlement fails (shares not delivered on time) peaked at 95,444 shares on Sep 18, 2026 over the last 90 days.

See a number that looks wrong?